Interstitial lung diseases (ILDs) represent a heterogeneous group of over 200 lung disorders, characterized by inflammation and fibrosis of the pulmonary interstitium. This article aims to provide a comprehensive understanding of the spectrum of ILDs, highlighting their pathogenesis, clinical manifestations, and management strategies.
ILDs are primarily caused by repeated or persistent injury to the lung parenchyma by various inhaled substances or systemic diseases. The injury leads to an abnormal healing response, resulting in fibrosis and architectural distortion of the lungs. The etiologies can be categorized into idiopathic, connective tissue disease-associated, and environmental or occupational.
Patients with ILDs often present with non-specific symptoms such as chronic cough, dyspnea, and fatigue. Physical examination may reveal crackles, clubbing, or signs of pulmonary hypertension. Pulmonary function tests typically show a restrictive pattern with reduced diffusing capacity. High-resolution computed tomography is the gold standard for diagnosis, often showing reticular opacities, honeycombing, and traction bronchiectasis.
Management of ILDs is primarily aimed at halting disease progression, alleviating symptoms, and improving quality of life. Treatment strategies depend on the underlying etiology and may include corticosteroids, immunosuppressive agents, antifibrotic drugs, or lung transplantation. Patient education, pulmonary rehabilitation, and supportive care are also integral parts of management.
Understanding the spectrum of ILDs is crucial for healthcare professionals as these diseases pose significant morbidity and mortality. A high index of suspicion, thorough clinical evaluation, and appropriate use of diagnostic tools are key to early diagnosis. Tailored treatment strategies, along with supportive care, can greatly improve patient outcomes and quality of life.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation